Chest
Clinical InvestigationsSerum Leukotriene B4 Levels in Patients with Obstructive Pulmonary Disease
Section snippets
MATERIALS AND METHODS
Subjects in this study included persons with no known pulmonary disease, with bronchial asthma, or with COPD, as defined by the American Thoracic Society.19 The study was approved by the Institutional Review Board of the University of Missouri-Columbia School of Medicine, and all subjects gave informed consent. Patients were categorized as treated with CS if they were receiving oral prednisone therapy at the time of blood sampling. As dosages of prednisone varied at different times, an average
RESULTS
The results are summarized in Table 1, Table 2. Our normal population and both subgroups of patients with COPD were similar in age (mean ± SD, 65 ± 19, 60 ± 10, and 66 ± 9 years, respectively). Asthmatic subjects and asthmatic subjects receiving CS (mean ± SD] age of 30 ± 7 and 42 ± 16 years) were significantly younger than normal subjects and all patients with COPD.
The durations of disease and of treatment with bronchodilators were similar in all groups. There were only two current smokers,
DISCUSSION
Leukotriene B4 is a mediator of inflammation and has been associated with efflux of neutrophils into BALF in humans, as well as bronchial hyperreactivity in dogs.23,24
Elevated LTB4 concentrations have been reported in various body fluids in several allergic and inflammatory conditions.10,16,25, 26, 27 Increased serum LTB4 concentrations have been found in asthmatic subjects, smokers, patients with psoriasis, and those with bronchogenic carcinoma.10,12,13 Increased plasma concentrations have
REFERENCES (31)
- et al.
Effects of topical 5-aminosalicylic acid and prednisolone on prostaglandin E2 and leukotriene B4 levels determined by equilibrium in vivo dialysis of rectum in relapsing ulcerative colitis
Gastroenterology
(1986) Overview of corticosteroid therapy
J Allergy Clin Immunol
(1985)- et al.
The metabolism “in vitro” of leukotriene B4 in blood of normal subjects and asthmatic patients
Prostaglandins
(1988) - et al.
Leukotrienes LTC4 and LTB4 in bronchoalveolar lavage in bronchial asthma and other respiratory diseases
J Allergy Clin Immunol
(1989) - et al.
Leukotriene B4 as a mediator of early and late reactions to antigen in humans: the effect of systemic glucocorticoid treatment in vivo
J Allergy Clin Immunol
(1989) - et al.
Increased activity of 5-lipoxygenase in polymorphonuclear leukocytes from asthmatic patients
Life Sci
(1985) - et al.
Metabolism of arachidonic acid in polymorphonuclear leukocytes: effects of the ionophore A23187
Proc Natl Acad Sci USA
(1979) - et al.
Enhanced 5-lipoxygenase activity in lung macrophages compared to monocytes from normal subjects
J Immunol
(1987) - et al.
Leukotriene B4, a potent chemokinetic and aggregating substance released from polymorphonuclear leukocytes
Nature
(1980) - et al.
Human alveolar macrophages produce leukotriene B4
Proc Natl Acad Sci USA
(1982)
Generation of leukotriene B4 by human lung fragments and purified human lung mast cells
Am Rev Respir Dis
Complement-receptor enhancement and chemotaxis of human neutrophils and eosinophils by leukotrienes and other lipoxygenase product
Clin Exp Immunol
Relative contribution of leukotriene B4 to the neutrophil chemotactic activity produced by the resident human alveolar macrophage
J Clin Invest
Differential effects of leukotriene B4 on T4 + and T8 + lymphocyte phenotype and immunoregulatory functions
J Immunol
Effect of lipoxygenase metabolites of arachidonic acid on proliferation of human T cells and T cell subsets
J Immunol
Cited by (51)
Prospective new amidinothiazoles as leukotriene B4 inhibitors
2019, Journal of Molecular StructureCitation Excerpt :In addition, LTB4 serves as a potent chemoattractant through ligation of the high affinity LTB4 receptor-1 (BLT1) on target cells. ([1,2]. Various inflammatory diseases, including asthma [3,4], allergic rhinitis [5], atopic dermatitis [5], allergic conjunctivitis [6], rheumatoid arthritis [7], chronic obstructive pulmonary disease (COPD) [8], obliterated bronchiolitis after lung transplantation [9], and interstitial lung diseases [10], are associated with increased levels of LTB4 and/or BLT1 expression. In some of the aforesaid diseases LTB4 levels reflect disease activity and are decreased by treatment [5].
Ultrapressure liquid chromatography–tandem mass spectrometry assay using atmospheric pressure photoionization (UPLC-APPI-MS/MS) for quantification of 4-methoxydiphenylmethane in pharmacokinetic evaluation
2016, Journal of Pharmaceutical and Biomedical AnalysisCitation Excerpt :4-Methoxydiphenylmethane, (4-MDM, Fig. 1A) is a selective augmenter of Leukotriene A4 Hydrolase (LTA4H) aminopeptidase enzyme activity and a new anti-inflammatory compound for chronic obstructive pulmonary disease (COPD) [1]. LTA4H has been targeted in discovery of anti-inflammatory drugs for COPD as it plays a major role in the generation of leukotriene B4 (LTB4), a potent modulator associated with the chemotaxis of leukocytes in the lung such as neutrophils and monocytes [2–4]. LTA4H is a bifunctional enzyme having an epoxy hydrolase site and an aminopeptidase site [5,6].
New drug therapies for COPD
2014, Clinics in Chest MedicineCitation Excerpt :As such, selective PGD2 receptor antagonists (CRTh2 antagonists) are mainly in development for asthma.117 Serum concentrations of LTB4, a potent neutrophil chemoattractant, are increased in patients with COPD.118 LTB4 activates BLT1-receptors, which are expressed on neutrophils and T lymphocytes.
MK-0633, a potent 5-lipoxygenase inhibitor, in chronic obstructive pulmonary disease
2011, Respiratory MedicineCitation Excerpt :The underlying inflammation seen with COPD, particularly the small airways, includes macrophages, neutrophils, CD4 and CD8-positive T-cells, and B-cells.3 Leukotriene B4 (LTB4), a potent chemoattractant of both neutrophils and T-cells,4 is thought to be an important mediator of neutrophil recruitment and survival in COPD,5, 6 and increased levels have been shown in serum,7 induced sputum,8 and exhaled breath condensates9 in patients with COPD. Therefore, drugs that target LTB4 production could potentially reduce inflammation in COPD.
LC/MS/MS analysis of leukotriene B<inf>4</inf> and other eicosanoids in exhaled breath condensate for assessing lung inflammation
2009, Journal of Chromatography B: Analytical Technologies in the Biomedical and Life SciencesThe role of leukotriene B<inf>4</inf> in allergic diseases
2008, Allergology International
Supported in part by the Medical Research Service, Harry S. Truman Memorial Veterans Hospital, and the Department of Medicine, University of Missouri-Columbia School of Medicine.
Presented in abstract form at the 16th World Congress on Diseases of the Chest and 55th Annual Assembly, American College of Chest Physicians, Boston, Oct 29-Nov 2, 1989.